Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
LL-37 vs Thymogen
An educational, source-based comparison of LL-37 and Thymogen — how each peptide works, what it's researched for, and what to know before going deeper.
Human cathelicidin peptide with antimicrobial and immune-modulating activity.
The only human cathelicidin antimicrobial peptide. Research demonstrates broad antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory effects on neutrophils, macrophages, and wound healing.
- Chronic biofilm infections
- Wound healing and dermatology
- Innate immune modulation
- • Not FDA-approved.
- • Pro-inflammatory effects possible at higher doses.
A synthetic dipeptide (Glu-Trp) in the Khavinson bioregulator family. Research suggests modulation of thymic and immune cell gene expression, supporting T-cell maturation and innate immune response in aged models.
- Immunosenescence and age-related immune decline
- Post-infectious immune recovery
- Chronic fatigue and immune dysregulation
- • Russian bioregulator research; limited independent replication.
- • Not FDA-approved.
LL-37 vs Thymogen — Key differences
- Class: LL-37 is classified as Immune · Antimicrobial, while Thymogen is Immune · Bioregulator.
- Primary research focus: LL-37 — chronic biofilm infections; Thymogen — immunosenescence and age-related immune decline.
- Tag: Immune · Antimicrobial vs Immune · Bioregulator.